Liraglutide vs Retatrutide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Liraglutide

Liraglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog with 97% homology to native human GLP-1. FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). It was the first GLP-1 agonist approved specifically for obesity. Liraglutide has a shorter half-life than semaglutide (13 hours vs 7 days), requiring daily rather than weekly dosing.

Full details →

Retatrutide

Retatrutide (LY3437943) is a first-in-class triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it is currently in Phase 3 clinical trials and has demonstrated the highest weight loss of any obesity medication to date — up to 28.7% body weight reduction at 48 weeks. The triple-receptor mechanism represents the next evolution beyond dual agonists like tirzepatide.

Full details →

Side-by-Side Comparison

Aspect	Liraglutide	Retatrutide
Dose Range	600 mcg–3 mg	4 mg–12 mg
Frequency	1x daily	Less than daily
Cycle Length	16–52 weeks	—
Route	subcutaneous	subcutaneous
Mechanism	Liraglutide binds to the GLP-1 receptor, activating the same pathways as native GLP-1: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression. A C-16 fatty acid (palmitic acid) attached to Lys26 via a glutamic acid spacer enables albumin binding, extending the half-life from ~2 minutes (native GLP-1) to ~13 hours. Less potent albumin binding and shorter half-life compared to semaglutide necessitates once-daily dosing.	Retatrutide is a synthetic peptide that activates three incretin/metabolic hormone receptors: (1) GLP-1 receptor — appetite suppression, insulin secretion, delayed gastric emptying, (2) GIP receptor — enhanced insulin sensitivity, improved fat metabolism, (3) Glucagon receptor — increased energy expenditure, hepatic fat mobilization, thermogenesis. The glucagon receptor component is the key differentiator, adding an energy-expenditure mechanism absent from GLP-1 and dual GIP/GLP-1 agonists. The molecule uses a C20 fatty diacid for albumin binding, enabling once-weekly dosing.
Typical Dosage	For weight management (Saxenda): start at 0.6 mg daily for 1 week. Increase by 0.6 mg weekly until reaching 3.0 mg daily maintenance dose. For type 2 diabetes (Victoza): start at 0.6 mg daily for 1 week, increase to 1.2 mg. May increase to 1.8 mg if additional glycemic control is needed.	Phase 2 trial doses: 0.5 mg, 4 mg, 8 mg, and 12 mg weekly. The 12 mg dose produced maximum weight loss (28.7%). Phase 3 trials are evaluating doses up to 12 mg. Dose escalation schedule similar to other GLP-1s (start low, increase every 4 weeks). Final approved dosing not yet established — Phase 3 trials ongoing.
Administration	Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Administer once daily at any time, independent of meals. Store pens refrigerated before first use; after first use, store at room temperature or refrigerated for up to 30 days.	Subcutaneous injection, once weekly. Phase 3 trials use pre-filled single-dose pens. Not yet commercially available — estimated FDA approval ~2027-2028.
Side Effects	Very common (>10%): nausea (up to 40%), diarrhea, constipation, vomiting, decreased appetite, dyspepsia, abdominal pain. Higher rate of daily GI symptoms compared to weekly GLP-1s due to daily dosing peaks. Common (1-10%): headache, dizziness, fatigue, injection site reactions, increased heart rate.	Phase 2 data: nausea (up to 25%), diarrhea (up to 22%), vomiting (up to 15%), constipation, decreased appetite. GI side effects were dose-dependent and generally mild-to-moderate. Lower rates of nausea compared to semaglutide, potentially due to GIP component. Increased heart rate observed at higher doses.
Best For	Weight Loss Diabetes Management Cardiovascular Health	Weight Loss Diabetes Management